Biogen shares were upgraded from hold to buy by Citi Research on Tuesday. The firm has predicted a 15% rally over the next year as Biogen focuses on treating spinal muscular atrophy. Spinraza, is the company’s blockbuster drug which has shown positive results during clinical trials. “The real driver of shares over the next 12-18 … Continue reading “Biogen (BIIB) Gets Upgrade Because Of This Blockbuster Drug”
